COVID- 19 vaccination reduces new-onset fibromyalgia risk in survivors.

IF 7 1区医学 Q1 MEDICINE, GENERAL & INTERNAL

BMC Medicine Pub Date : 2025-05-01 DOI:10.1186/s12916-025-04069-z

Aihui Liu, PeiLun Liao, Hongyang Jiang, Shan Huang, Shinan Li, James Cheng-Chung Wei, Zhenhua Ying

{"title":"COVID- 19 vaccination reduces new-onset fibromyalgia risk in survivors.","authors":"Aihui Liu, PeiLun Liao, Hongyang Jiang, Shan Huang, Shinan Li, James Cheng-Chung Wei, Zhenhua Ying","doi":"10.1186/s12916-025-04069-z","DOIUrl":null,"url":null,"abstract":"Background: Numerous studies have demonstrated that COVID-19 is associated with an increased risk of new-onset fibromyalgia (FM), which not only significantly impacts patients' quality of life but also places a substantial burden on healthcare systems. However, no studies have yet investigated whether COVID-19 vaccination may mitigate the risk of developing new-onset FM in individuals who have survived COVID-19. This study aimed to assess the potential effect of COVID-19 vaccination in reducing the risk of new-onset FM among COVID-19 survivors.Methods: We utilized the data resources from the TriNetX platform to compare 90,508 COVID-19 survivors who received the COVID-19 vaccine with 90,508 unvaccinated survivors. The Cox proportional hazards regression model was used to estimate the hazard ratio (HR) and its corresponding 95% confidence interval (CI). The incidence was calculated using the Kaplan-Meier survival analysis method. Furthermore, we conducted detailed subgroup analyses and sensitivity analyses.Results: The cohort analysis of the present study revealed a significant reduction in the risk of new-onset FM among COVID-19 survivors who received the COVID-19 vaccine, compared to the unvaccinated group (HR 0.84; 95% CI 0.71-0.99). Notably, the results of the subgroup analysis indicated that the COVID-19 vaccine exerted a protective effect against the development of new-onset FM in males, individuals with a body mass index (BMI) < 30, and those with comorbid depression and anxiety.Conclusions: Our findings suggest that COVID-19 vaccination may play a protective role in reducing the risk of new-onset FM among COVID-19 survivors. The findings may indicate the importance of targeting vaccination to specific subgroups, such as males, individuals with lower BMIs, and those with mental health conditions, including depression and anxiety. This approach may enhance the protective effects of the vaccine and further reduce the incidence of long-term health complications associated with COVID-19. Further research is needed to validate these observations.","PeriodicalId":9188,"journal":{"name":"BMC Medicine","volume":"23 1","pages":"255"},"PeriodicalIF":7.0000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12046932/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12916-025-04069-z","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Numerous studies have demonstrated that COVID-19 is associated with an increased risk of new-onset fibromyalgia (FM), which not only significantly impacts patients' quality of life but also places a substantial burden on healthcare systems. However, no studies have yet investigated whether COVID-19 vaccination may mitigate the risk of developing new-onset FM in individuals who have survived COVID-19. This study aimed to assess the potential effect of COVID-19 vaccination in reducing the risk of new-onset FM among COVID-19 survivors.

Methods: We utilized the data resources from the TriNetX platform to compare 90,508 COVID-19 survivors who received the COVID-19 vaccine with 90,508 unvaccinated survivors. The Cox proportional hazards regression model was used to estimate the hazard ratio (HR) and its corresponding 95% confidence interval (CI). The incidence was calculated using the Kaplan-Meier survival analysis method. Furthermore, we conducted detailed subgroup analyses and sensitivity analyses.

Results: The cohort analysis of the present study revealed a significant reduction in the risk of new-onset FM among COVID-19 survivors who received the COVID-19 vaccine, compared to the unvaccinated group (HR 0.84; 95% CI 0.71-0.99). Notably, the results of the subgroup analysis indicated that the COVID-19 vaccine exerted a protective effect against the development of new-onset FM in males, individuals with a body mass index (BMI) < 30, and those with comorbid depression and anxiety.

Conclusions: Our findings suggest that COVID-19 vaccination may play a protective role in reducing the risk of new-onset FM among COVID-19 survivors. The findings may indicate the importance of targeting vaccination to specific subgroups, such as males, individuals with lower BMIs, and those with mental health conditions, including depression and anxiety. This approach may enhance the protective effects of the vaccine and further reduce the incidence of long-term health complications associated with COVID-19. Further research is needed to validate these observations.

查看原文本刊更多论文

COVID- 19疫苗接种可降低幸存者新发纤维肌痛的风险。

背景：大量研究表明，COVID-19与新发纤维肌痛（FM）风险增加有关，这不仅会严重影响患者的生活质量，而且会给医疗保健系统带来沉重负担。然而，尚未有研究调查COVID-19疫苗接种是否可以降低COVID-19幸存者发生新发FM的风险。本研究旨在评估COVID-19疫苗接种在降低COVID-19幸存者新发FM风险方面的潜在作用。方法：利用TriNetX平台的数据资源，将接种COVID-19疫苗的90,508名COVID-19幸存者与未接种疫苗的90,508名幸存者进行比较。采用Cox比例风险回归模型估计风险比（HR）及其相应的95%置信区间（CI）。发生率采用Kaplan-Meier生存分析方法计算。此外，我们还进行了详细的亚组分析和敏感性分析。结果：本研究的队列分析显示，与未接种疫苗组相比，接种COVID-19疫苗的COVID-19幸存者新发FM的风险显著降低(HR 0.84；95% ci 0.71-0.99)。值得注意的是，亚组分析结果表明，COVID-19疫苗对具有体重指数（BMI）的男性中新发FM的发展具有保护作用。结论：我们的研究结果表明，COVID-19疫苗接种可能对降低COVID-19幸存者中新发FM的风险具有保护作用。研究结果可能表明，针对特定亚群体接种疫苗的重要性，如男性、bmi较低的个体，以及有精神健康状况（包括抑郁和焦虑）的人。这种方法可以增强疫苗的保护作用，并进一步减少与COVID-19相关的长期健康并发症的发生率。需要进一步的研究来验证这些观察结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMC Medicine 医学-医学：内科

CiteScore

13.10

自引率

1.10%

发文量

435

审稿时长

4-8 weeks

期刊介绍： BMC Medicine is an open access, transparent peer-reviewed general medical journal. It is the flagship journal of the BMC series and publishes outstanding and influential research in various areas including clinical practice, translational medicine, medical and health advances, public health, global health, policy, and general topics of interest to the biomedical and sociomedical professional communities. In addition to research articles, the journal also publishes stimulating debates, reviews, unique forum articles, and concise tutorials. All articles published in BMC Medicine are included in various databases such as Biological Abstracts, BIOSIS, CAS, Citebase, Current contents, DOAJ, Embase, MEDLINE, PubMed, Science Citation Index Expanded, OAIster, SCImago, Scopus, SOCOLAR, and Zetoc.